BioSpace News Archive

Innovative qPCR platform simplifies molecular diagnostic workflows for infectious disease, oncology and COVID-19 testing

Caraway Therapeutics today announced that the Company is scheduled to participate at two upcoming virtual investor events in April 2021. Caraway’s Chief Executive Officer, Martin D. Williams, will present at the Stifel CNS Day on April 1, 2021 at 2:30pm ET and the Company is participating in the Needham Annual Healthcare Conference on April 13, 2021.

Visus Therapeutics Inc., a clinical-stage pharmaceutical company in pursuit of developing the world’s first presbyopia-correcting eye drop with the potential to last a minimum of eight hours, today announced the commencement of its Phase 2 clinical trial of BRIMOCHOL™

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, is scheduled to participate in a panel discussion at the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference,

Continued progress in dosing of patients in clinical trial of NKX101, investigational CAR NK cell therapy engineered with NKG2D receptor, in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) Interim top-line data from NKX101 clinical trial expected by end of 2021

Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3Kα mutant selective inhibitor in 2021 Entered into a global collaboration with Genentech for the development and commercialization of RLY-1971 Continued to advance three additional oncology preclinical programs and extended work outside of oncology into genetic diseases with two preclinical programs

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at Stifel’s 3 rd Annual CNS Day on Thursday, Apr. 1, 2021 at 8:30 a.m. ET ( 1:30 p.m. BST ). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Chemence, a global company with specialized expertise in the field of polymerizable technology, announced the opening of the Chemence Center of Excellence, a state-of-the-art research and development facility in Alpharetta, Georgia.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that management will be participating in the following virtual investor conferences: Guggenheim Healthcare Talks—Genomic Medicines

MAIA Biotechnology, Inc. , a biotechnology company focused on the development of targeted, first-in-class oncology drugs, today announced that company management is presenting at the following virtual investor conferences: